AzTrials
AzTrials

DepressionNCT01327404

Myelin, Glia and Depression in Type 2 Diabetes

An observational study of Depression and Diabetes Mellitus, run by University of Illinois Chicago at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to examine the relationship between brain structure and depression in adults aged 30 or older with Diabetes. This relationship is determined using magnetic resonance imaging technology (MRI), a scanner with a magnet that is used to create images of the brain. Read more about this study

Who is it for?
Ages 30 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Depression, Diabetes Mellitus
How many people
400 participants
Where
1 siteUnited States
Study dates
19 Oct 2009to Nov 2014
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients of all subject types will be recruited through the general medical, psychiatric, and endocrinology clinics associated with the UIC Medical Center. Patients will be first cleared for participation in the study by their primary physicians. The patient and family will be approached by the PI or another investigator who will explain the research and its goals. We also plan to recruit subjects through flyers and advertisements.

Who may be able to join

  • Age: 30 to 80 years old
  • Diagnosis of type 2 diabetes
  • Diagnosis of major depressive disorder using standard diagnostic and statistical manual (DSM) criteria
  • Score of 15 or greater on the 17-item Hamilton Depression rating scale
  • Mini Mental Status Exam score of 24 or greater
  • No evidence of clinical dementia or any other clinical brain disorder
  • Free of psychotropic/psychoactive medications for at least 2 weeks
  • First episode of depression diagnosed either after or around the time type 2 diabetes was diagnosed since we are interested in the relationship between the cerebrovascular effect of diabetes and the pathophysiology of major depression

Who cannot join

  • Presence of dementia or any other clinical brain disorder (Parkinson's, Alzheimer's)
  • Mini Mental Status Exam score of less than 24
  • Unstable medical illness (grade 4 on the Cumulative Illness Rating Scale)
  • Presence of any metallic implant that would preclude an MRI scan (pacemaker, etc.)
  • Concurrent Axis 1 disorder (schizophrenia, bipolar)
  • Use of atypical neuroleptics for the current episode and/or strong clinical suspicion that the diabetes is secondary to the use of atypical neuroleptics;
Show all 17Show fewer
  • Recurrent major depression, operationally defined as two or more, well-characterized episodes of depression, prior to the onset/diagnosis of diabetes
  • Seizure disorder
  • Stroke/Transient Ischemic Attack
  • Central nervous system disorder (multiple sclerosis)
  • Trauma to head/Loss of Consciousness
  • Claustrophobia
  • Eating disorder (anorexia, bulimia)
  • Weight of over 350 pounds
  • Learning disorder (dyslexia, ADHD)
  • Psychosis, panic or anxiety disorder outside the context of depression
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Illinois

    Chicago, Illinois, 60612

Other trials in United States

About this study

The purpose of the study is to examine the relationship between brain structure and depression in adults aged 30 or older with Diabetes. This relationship is determined using magnetic resonance imaging technology (MRI), a scanner with a magnet that is used to create images of the brain.

Read the detailed description

Diabetes is a major health problem affecting approximately 18 million Americans. It is a growing crisis that has devastating complications including heart disease, peripheral neuropathy and renal failure. According to a literature review by Gavard et al, the prevalence of major depression in a sample diabetic population in controlled studies was 8.5 to 27.3% (mean prevalence of 14.0%). This was estimated to be up to three times the prevalence of major depression in the general U.S. adult population. Diabetes and major depression are mutual risk factors, with diabetic patients more likely to develop major depression with an odds ratio of 2.5 and depressed patients being more likely to develop type 2 diabetes with an estimated relative risk of 2.2. Depression also has a significant impact on the course of diabetes, leading to higher rates of hyperglycemia and diabetic complications. Depression in patients with diabetes is also associated with poor compliance, decreased quality of life, increased disability and greater health care utilization. A recent 8-year follow-up study of patients with diabetes and depression concluded that the coexistence of these illnesses is associated with a significantly increased risk of death from all causes beyond that due to either depression or diabetes alone. In this study, patients with diabetes and depression had a 1.3-fold increased risk of death from all causes when compared with patients with diabetes alone and a 2-fold increased risk of death when compared with patients with only depression. Reports from a prospective, community-based study in western Australia suggest that the behavioral consequences of depression, including non-compliance with medication and exercise regimens, contribute to increased mortality in these patients.

TRIAL OBJECTIVES AND PURPOSE Specific Aim 1: To study the biophysical properties of the white and gray matter in critical cortical and subcortical regions using magnetization transfer in patients with type 2 diabetes and MDD, non-depressed diabetic controls, patients with unipolar depression without diabetes and nondiabetic healthy controls. The investigators are interested in the separate and cumulative effects of both diabetes and depression on Magnetization Transfer Ratios (MTR) in different brain regions.

Hypothesis: The overarching hypothesis is that both diabetes and depression have the effect of lowering magnetization transfer ratios (MTR) in the anterior cingulate cortex, subcortical nuclei (head of the caudate nucleus and putamen) and the frontal white matter. These effects are cumulative and may not be additive in some regions. Our pilot data suggest that MTR will be lower in these regions in patients with type 2 diabetes (both with and without depression) when compared with healthy controls. In some regions (eg. head of the caudate nucleus - see preliminary data) the investigators anticipate that patients with diabetes and MDD will have the lowest and healthy controls will have the highest MT ratios. The group with unipolar depression without diabetes and the diabetic controls will have MT ratios that fall between these two groups. In other regions of interest, both groups with diabetes will have values significantly different from healthy controls, with patients diagnosed with unipolar depression falling between the healthy and diabetic groups.

Specific Aim 2: To examine levels of glutamate and aspartate (creatine ratios) in two regions involved in the regulation of mood and cognition - the bilateral anterior cingulate cortex and the left subcortical region (the head of the caudate nucleus and the putamen) in patients with type 2 diabetes and our three comparison groups.

Hypothesis: Levels of glutamate and aspartate (creatine ratios) will be lower in patients with combined Type 2 Diabetes and MDD when compared with non-depressed diabetic patients and healthy controls. Our pilot data provide little basis to expect a simple effect of diabetes alone but do not rule out an interaction such that effects are only seen, or are worsened, by the combination of diabetes and depression. The inclusion of a depressed non-diabetic group in the current design will make it possible to evaluate whether the observed effect in the doubly-diagnosed group is best viewed as an effect of depression alone or as an interaction in which diabetes plays a role.

Specific Aim 3: To examine the relationship between regional MTRs and specific cognitive domains in subjects in all four groups.

Hypothesis: There will be direct correlations in all study groups between MT ratios in the subcortical nuclei, anterior cingulate cortex and the dorsolateral white matter and performance on specific cognitive domains, including attention, executive functions, learning and memory and psychomotor processing.

Exploratory Aim 1: In an exploratory manner the investigators will estimate cerebral blood volume, a measure of the cerebral microvasculature, in critical brain regions involved in frontal-subcortical circuitry (anterior cingulate, dorsolateral white, head of the caudate nucleus and the putamen) in subjects in our depressed diabetic group and the three comparison groups using dynamic susceptibility contrast MR imaging (perfusion-weighted MR imaging).

Exploratory Aim 2: A comparison of blood samples from healthy controls, diabetic subjects, depressed subjects and subjects with both depression and diabetes to see if there is evidence of differences in plasma neurotransmitter levels, hypothalamic-pituitary-adrenals (HPA) axis, and immune function between these four subject groups

Keywords
Depression, Diabetes Mellitus
Medical subject headings
Depression, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01327404
Study groupRoleWhat they receive
DepressedPatients with Major Depressive Disorder
DiabeticPatients with Type 2 Diabetes
Diabetic/DepressedPatients with both diabetes and major depressive disorder
Healthy ControlsNot described

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Apr 2011 (estimated)
  2. Study start19 Oct 2009
  3. Primary completion7 Oct 2014
  4. Study completionNov 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
400 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01327404
Sponsor's protocol ID
2009-0473
Other IDs
5R01MH063764
Status last verified
May 2025
First submitted
30 Mar 2011
Last updated
20 May 2025
Results posted
No
Data monitoring committee
Yes

Publications

  • Ajilore O, Narr K, Rosenthal J, Pham D, Hamilton L, Watari K, Elderkin-Thompson V, Darwin C, Toga A, Kumar A. Regional cortical gray matter thickness differences associated with type 2 diabetes and major depression. Psychiatry Res. 2010 Nov 30;184(2):63-70. doi: 10.1016/j.pscychresns.2010.07.003. Epub 2010 Sep 15.

    PubMed 20832254
  • Nguyen TT, Wong TY, Islam FM, Hubbard L, Ajilore O, Haroon E, Darwin C, Esser B, Kumar A. Evidence of early retinal microvascular changes in patients with type 2 diabetes and depression. Psychosom Med. 2010 Jul;72(6):535-8. doi: 10.1097/PSY.0b013e3181da90f4. Epub 2010 Apr 5.

    PubMed 20368470
  • Kumar A, Gupta R, Thomas A, Ajilore O, Hellemann G. Focal subcortical biophysical abnormalities in patients diagnosed with type 2 diabetes and depression. Arch Gen Psychiatry. 2009 Mar;66(3):324-30. doi: 10.1001/archgenpsychiatry.2008.548.

    PubMed 19255382
  • Watari K, Elderkin-Thompson V, Ajilore O, Haroon E, Darwin C, Pham D, Kumar A. Neuroanatomical correlates of executive functioning in depressed adults with type 2 diabetes. J Clin Exp Neuropsychol. 2008 May;30(4):389-97. doi: 10.1080/13803390701440486.

    PubMed 18938677

Questions about this trial

What is this clinical trial studying?

An observational study of Depression and Diabetes Mellitus, run by University of Illinois Chicago at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01327404, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in